These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 27569102)

  • 1. Abiraterone acetate as a possible cause of sudden cardiac death.
    Sahin S; Karatas F; Eren T; Altinbas M; Altundag K
    J BUON; 2016; 21(3):751-2. PubMed ID: 27569102
    [No Abstract]   [Full Text] [Related]  

  • 2. Abiraterone acetate and acute leukemia: a casual association?
    Bolzacchini E; Patriarca C; Giordano M
    Anticancer Drugs; 2021 Jan; 32(1):102-104. PubMed ID: 32932280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible that one patient may again experience a response to abiraterone acetate withdrawal during an abiraterone acetate rechallenge?
    Maines F; Veccia A; Caffo O
    Eur Urol; 2014 Jul; 66(1):179-80. PubMed ID: 24685435
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors.
    Procopio G; Grassi P; Testa I; Verzoni E; Torri V; Salvioni R; Valdagni R; de Braud F
    Am J Clin Oncol; 2015 Oct; 38(5):479-82. PubMed ID: 24064757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France.
    Houédé N; Beuzeboc P; Gourgou S; Tosi D; Moise L; Gravis G; Delva R; Fléchon A; Latorzeff I; Ferrero JM; Oudard S; Tartas S; Laguerre B; Topart D; Roubaud G; Agherbi H; Rebillard X; Azria D
    BMC Cancer; 2015 Apr; 15():222. PubMed ID: 25884302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid oral desensitization protocol to abiraterone acetate.
    Verdu M; Torres-Degayon V; Hassan-Bennis M
    Ann Allergy Asthma Immunol; 2018 Jun; 120(6):668-669. PubMed ID: 29432966
    [No Abstract]   [Full Text] [Related]  

  • 8. Low dose versus standard dose of corticosteroids in the management of adverse events of special interest from abiraterone acetate: data from a literature-based meta-analysis.
    Roviello G; Corona SP; Generali D
    Med Oncol; 2017 Aug; 34(10):166. PubMed ID: 28852974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant.
    van Nuland M; Janssen JM; van Hoek B; Rosing H; Beijnen JH; Bergman AM
    Clin Genitourin Cancer; 2019 Oct; 17(5):e893-e896. PubMed ID: 31248829
    [No Abstract]   [Full Text] [Related]  

  • 11. Abiraterone Acetate-Associated Acute Pancreatitis: A Case Report.
    Buyuksimsek M; Ogul A; Yetisir AE; Koseci T; Sumbul HE
    Am J Ther; 2023 May; 30(3):e296-e298. PubMed ID: 34010162
    [No Abstract]   [Full Text] [Related]  

  • 12. [A Case of Fulminant Hepatitis after Administration of Abiraterone Acetate].
    Yumiba S; Komori K; Iwanishi T; Koida Y; Kobayashi M; Ono Y
    Hinyokika Kiyo; 2017 Nov; 63(11):479-482. PubMed ID: 29232800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should LHRH therapy be continued in patients receiving abiraterone acetate?
    Ah-Thiane L; Supiot S
    Prostate Cancer Prostatic Dis; 2022 Apr; 25(4):798-799. PubMed ID: 36028658
    [No Abstract]   [Full Text] [Related]  

  • 14. Initial experience with abiraterone acetate in patients with castration-resistant prostate cancer.
    Beardo-Villar P; Ledo-Cepero MJ; Gavira-Moreno R; Soto-Delgado M; Soto-Villalba J; Alvarez-Ossorio JL; Juárez-Soto A
    Actas Urol Esp; 2014 Jun; 38(5):339-45. PubMed ID: 24480574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
    Maines F; Caffo O; De Giorgi U; Fratino L; Lo Re G; Zagonel V; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Basso U; Fraccon AP; Vicario G; Conteduca V; Galligioni E
    Clin Genitourin Cancer; 2016 Feb; 14(1):48-55. PubMed ID: 26382222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.
    Han CS; Patel R; Kim IY
    Expert Opin Drug Metab Toxicol; 2015 Jun; 11(6):967-75. PubMed ID: 25936418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of chemotherapy in the treatment of metastatic castration-resistant prostate cancer patients who have progressed after abiraterone acetate.
    Petrioli R; Francini E; Laera L; Fiaschi AI; Ponchietti R; Roviello G
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):439-45. PubMed ID: 26082421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
    Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
    Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
    [No Abstract]   [Full Text] [Related]  

  • 19. [Not Available].
    Miller K
    Oncol Res Treat; 2017; 40 Suppl 2():6-7. PubMed ID: 28365705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
    Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
    Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.